Cabozantinib Formulation Stabilization via Crystalline Form-S
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cabozantinib pharmaceutical compositions face challenges with chemical and physical instability, leading to degradation issues and the formation of dimer impurities, which affect stability, bioavailability, and shelf life.
Innovation Solution
A pharmaceutical composition comprising N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate with a dimer impurity of less than 2.0% as measured by HPLC, formulated with pharmaceutically acceptable carriers and excipients, enhancing stability and shelf life through improved formulation techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Cabozantinib is formulated as a pharmaceutical composition, then it can be used for treatment, but it degrades chemically and physically forming dimer impurities
Solution Approach 1:
The patent applies parameter changes by optimizing formulation parameters including using specific crystalline forms (crystalline form-S), controlling particle size distribution, adjusting pH buffers, and selecting specific excipients to stabilize Cabozantinib and prevent dimer formation. The formulation maintains dimer impurity levels below 2.0% through these controlled parameter changes.
Solution Approach 2:
The patent uses excipients as intermediary substances that mediate between Cabozantinib and the environment. These excipients include pH buffers, surfactants, and stabilizers that protect the active ingredient from degradation while maintaining its therapeutic effectiveness. The crystalline form-S acts as an intermediary stable state that resists conversion to degraded forms.
2Duration of action of stationary object
If Cabozantinib is stored for extended periods, then shelf life increases, but stability decreases due to degradation
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing Cabozantinib in a specific crystalline form-S during manufacturing, before storage. This preliminary stabilization ensures that the drug maintains its chemical integrity throughout the extended shelf life period. The formulation is designed with pre-selected excipients and pH conditions that prevent degradation pathways from initiating during storage.
Solution Approach 2:
The patent utilizes phase transition principles by maintaining Cabozantinib in a specific crystalline phase (crystalline form-S) that is thermodynamically stable. This crystalline phase resists conversion to amorphous or degraded phases during storage, thereby maintaining chemical stability over extended periods. The formulation controls moisture and temperature conditions to prevent unwanted phase transitions.
3Manufacturing precision
If formulation techniques are improved to reduce dimer impurities, then purity increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by focusing stabilization efforts on specific critical aspects of the formulation rather than attempting to control all parameters. The key local quality controls include maintaining specific pH ranges (using buffers), controlling moisture content, and ensuring proper crystalline form-S development during manufacturing. This targeted approach achieves high purity without requiring complex control of all formulation parameters.
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N′-(4-fluoro phenyl) cyclopropane-1,1-dicarboxamide, (2S)-hydroxy butanedioate of formula-1and a pharmaceutically acceptable carrier wherein the said pharmaceutical composition has a dimer impurity of formula-2 less than about 2.0% as measured by HPLC.